The results of MS-HRM indicated that the hypermethylation ratios of the tested regions in the 4 candidate genes were significantly higher in the tumor than in the paired normal samples (STXBP6: 55.6% vs. 20%, p = 0.001; BCL6B: 68.9% vs. 40%, p = 0.006; FZD10: 93.3% vs. 77.8%, p = 0.036; HSPB6: 91.1% vs. 68.9%, p = 0.008) (the data is showed in Fig 3 and S6 Table). This evidence concerns the gene STXBP6 and neoplasm.